Singapore, Oct. 9 -- Japan's startup Alpha Fusion Inc. has announced a joint initiative with the Kobe City Medical Center General Hospital (KCGH) to establish a domestic supply system for investigational drugs utilising Astatine-211 (At-211). This collaboration significantly advances the foundational work for what is expected to be the world's first company-sponsored clinical trial using At-211.

KCGH has secured usage approval for At-211 from Nuclear Regulation Authority. The hospital is now proceeding with technology transfer and test manufacturing of the investigational drug for Alpha Fusion's lead pipeline, af-001 (targeting differentiated thyroid cancer), in preparation for clinical trial initiation. This pioneering effort is setting...